rivastigmine has been researched along with Cognitive Decline in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (76.00) | 24.3611 |
| 2020's | 6 (24.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulshreshtha, A; Piplani, P | 1 |
| Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Srivastava, P; Tiwari, V; Tripathi, A; Tripathi, MK; Tripathi, PN | 1 |
| Choubey, PK; Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Tripathi, A; Tripathi, MK; Tripathi, PN | 1 |
| Cui, Y; Ren, G; Shi, X; Xu, Z | 1 |
| ArianNik, M; Fathi, M; Hannani, KK; Massoudi, N; Mohit, B; Nooraei, N | 1 |
| Ahuja, M; Gabor, C; Karimi, A; Lee, J; Lewis, K; Patterson, C; Reppas-Rindlisbacher, C; Siddhpuria, S; Sood, E; Wong, E | 1 |
| Çinar, N; Şahiner, TAH | 1 |
| Aldridge, GM; Anderson, SW; Narayanan, NS; Uc, EY; Zhang, Q | 1 |
| Gupta, P; Mishra, A; Pal, A; Singh, A; Singh, S; Tiwari, S | 1 |
| Clotet, B; Díez-Quevedo, C; Ferrer, MJ; Fumaz, CR; Garolera, M; Miranda, C; Moltó, J; Muñoz-Moreno, JA; Pérez-Álvarez, N; Prats, A | 1 |
| Beckers, N; Dietlein, M; Fink, GR; Kracht, L; Kukolja, J; Neumaier, B; Onur, OA; Richter, N; Tittgemeyer, M | 1 |
| de Jong, IEM; Koshy Cherian, A; Kucinski, A; Sarter, M; Wu, R | 1 |
| Bando, N; Hirano, T; Ishikawa, I; Matsumoto, Y; Mori, I; Mori, T; Nakamura, Y; Park, H; Tanaka, M; Tsuno, N | 1 |
| Chen, MH; Chen, Q; Ibrahim, JG; Ohlssen, D | 1 |
| Ashoor, HM; Berliner, S; Chen, MH; Hemmelgarn, B; Ho, JM; Ng, CH; Soobiah, C; Straus, SE; Tricco, AC | 1 |
| Attar, M; Caltagirone, C; Colombo, D; Cravello, L; Padovani, A; Sorbi, S; Spalletta, G | 1 |
| Brunetti, V; Della Marca, G; Lapenta, L; Losurdo, A; Mariotti, P; Marra, C; Rossini, PM; Testani, E | 1 |
| Shoji, M | 1 |
| Mamikonyan, E; Melvin, E; Weintraub, D; Xie, SX | 1 |
| Li, Z; Sun, C; Wang, J; Wang, P; Yu, Z; Zhang, J | 1 |
| Ransmayr, G | 1 |
| Gruca, P; Lason-Tyburkiewicz, M; Papp, M; Willner, P | 1 |
| Bokde, AL; Born, C; Cavedo, E; Dubois, B; Faltraco, F; Galluzzi, S; Hampel, H; Lista, S; Lopez-Bayo, P; Meindl, T; Möller, HJ; Reiser, M; Teipel, SJ | 1 |
| Choi, BS; Ha, YC; Kim, S; Lee, JY; Shin, HW; Youn, YC | 1 |
| Natali, B; Taffet, GE; Wagle, KC | 1 |
6 review(s) available for rivastigmine and Cognitive Decline
| Article | Year |
|---|---|
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta-analysis.
Topics: Accidental Falls; Accidental Injuries; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Fractures, Bone; Galantamine; Humans; Rivastigmine; Syncope | 2023 |
Approach to Cognitive Impairment in Parkinson's Disease.
Topics: Arousal; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Executive Function; Humans; Memory, Episodic; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Transcutaneous Electric Nerve Stimulation | 2020 |
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Parkinson Disease; Risk Factors; Rivastigmine | 2015 |
6 trial(s) available for rivastigmine and Cognitive Decline
| Article | Year |
|---|---|
The impact of rivastigmine on post-surgical delirium and cognitive impairment; a randomized clinical trial.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Delirium; Humans; Phenylcarbamates; Rivastigmine | 2023 |
Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
Topics: Administration, Cutaneous; Adult; Anti-Retroviral Agents; Cognitive Dysfunction; Executive Function; Female; HIV Infections; Humans; Lithium; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Pilot Projects; Rivastigmine; Treatment Outcome | 2017 |
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
Topics: Aged; Cholinesterase Inhibitors; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Rivastigmine | 2015 |
Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.
Topics: Accidental Falls; Aged; Cholinesterase Inhibitors; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Parkinson Disease; Rivastigmine | 2015 |
Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.
Topics: Aged; Aged, 80 and over; Amnesia; Attention; Brain; Brain Mapping; Cognitive Dysfunction; Double-Blind Method; Facial Recognition; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Rivastigmine; Visual Pathways | 2016 |
Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Delirium; Female; Hip Fractures; Humans; Incidence; Male; Multivariate Analysis; Odds Ratio; Postoperative Complications; Prospective Studies; Risk Factors; Rivastigmine | 2017 |
13 other study(ies) available for rivastigmine and Cognitive Decline
| Article | Year |
|---|---|
Ameliorative effects of amide derivatives of 1,3,4-thiadiazoles on scopolamine induced cognitive dysfunction.
Topics: Acetylcholinesterase; Amides; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cognitive Dysfunction; Drug Design; Humans; Maze Learning; Mice; Molecular Docking Simulation; Protein Conformation; Scopolamine; Thiadiazoles | 2016 |
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cognitive Dysfunction; Drug Design; Humans; Mice; Piperidines; Protein Aggregation, Pathological; Structure-Activity Relationship | 2019 |
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Female; Humans; Kinetics; Molecular Docking Simulation; Neuroprotective Agents; Oxadiazoles; Piperazines; Protein Aggregates; Pyridines; Rats, Wistar; Structure-Activity Relationship | 2019 |
Effects of the online computerized cognitive training program BEYNEX on the cognitive tests of individuals with subjective cognitive impairment and Alzheimer’s disease on rivastigmine therapy
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Rivastigmine; Therapy, Computer-Assisted | 2020 |
Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signalling.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Apoptosis; Cognitive Dysfunction; Endoplasmic Reticulum Stress; Male; Neuroprotective Agents; Proteolysis; Rats; Rats, Sprague-Dawley; Rivastigmine; Streptozocin | 2021 |
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
Topics: Acetates; Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cerebral Cortex; Cholinergic Agents; Cognitive Dysfunction; Female; Humans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Oxygen; Piperidines; Positron-Emission Tomography; Rivastigmine | 2018 |
Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.
Topics: Accidental Falls; Animals; Basal Forebrain; Benzylamines; Cholinesterase Inhibitors; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Female; Indoles; Male; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rivastigmine; Serotonin Antagonists | 2019 |
Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
Topics: Aged, 80 and over; Alzheimer Disease; Appetite; Attitude to Health; Body Weight; Cholinesterase Inhibitors; Cognitive Dysfunction; Eating; Female; Humans; Male; Mental Status and Dementia Tests; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2019 |
Bayesian modeling and inference for clinical trials with partial retrieved data following dropout.
Topics: Algorithms; Bayes Theorem; Cognitive Dysfunction; Data Interpretation, Statistical; Humans; Markov Chains; Models, Statistical; Monte Carlo Method; Patient Dropouts; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2013 |
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Topics: Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Cognitive Dysfunction; Depression; Drug Substitution; Humans; Italy; Mood Disorders; Phenylcarbamates; Rivastigmine; Socioeconomic Factors | 2014 |
Rivastigmine for refractory REM behavior disorder in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Polysomnography; REM Sleep Behavior Disorder; Rivastigmine; Time Factors | 2014 |
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Cholinesterase Inhibitors; Cognitive Dysfunction; Depressive Disorder; Disease Models, Animal; Donepezil; Indans; Male; Nootropic Agents; Piperidines; Rats; Rats, Wistar; Recognition, Psychology; Rivastigmine; Stress, Psychological | 2016 |
Cholinesterase inhibitor initiation in hospital setting.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Delirium; Diagnosis, Differential; Disease Progression; Early Termination of Clinical Trials; Hospitalization; Humans; Intensive Care Units; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |